Parenteral Nutrition

Parenteral Nutrition

Global Parenteral Nutrition Market to Reach US$11.8 Billion by 2030

The global market for Parenteral Nutrition estimated at US$7.5 Billion in the year 2023, is expected to reach US$11.8 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2023-2030. Single Dose Amino Acid Solution, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in the Parenteral Lipid Emulsion segment is estimated at 7.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 10.3% CAGR

The Parenteral Nutrition market in the U.S. is estimated at US$2.0 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.9 Billion by the year 2030 trailing a CAGR of 10.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Parenteral Nutrition Market - Key Trends and Drivers Summarized

Parenteral nutrition (PN) is a critical method in medical nutrition therapy where nutrients are supplied directly into the bloodstream, bypassing the gastrointestinal tract. This advanced feeding technique is essential for individuals whose nutritional needs cannot be met through traditional oral or enteral routes due to various health conditions. PN involves administering a mixture of carbohydrates, lipids, vitamins, amino acids, electrolytes, water, and trace elements through a catheter inserted into a vein. This method can be tailored to meet either complete or supplemental nutritional needs, depending on the patient`s specific health situation. PN is typically considered when enteral routes are inadequate or inappropriate due to conditions like bowel obstructions, severe intestinal failure, high output fistulas, or recurrent vomiting.

The technology and practice of PN have evolved to address both short-term and long-term nutritional needs. Short-term PN is often used to supplement a patient`s diet when oral intake is insufficient but still possible, providing partial nutritional support. In contrast, Total Parenteral Nutrition (TPN) serves as the sole source of nutrients for patients who cannot obtain nutrition via the gastrointestinal tract, offering complete nutritional support through intravenous delivery. There are different types of PN based on the method and duration of delivery, including Central Parenteral Nutrition, which delivers nutrients through a large central vein, and Peripheral Parenteral Nutrition, administered through smaller veins and suitable for short-term or partial nutrition. Despite its life-sustaining benefits, PN comes with potential risks such as catheter-related issues, nutrient imbalances, liver dysfunction, and metabolic disturbances, which require careful management and monitoring by healthcare professionals.

The growth of PN, particularly Home Parenteral Nutrition (HPN), is driven by several key factors. Innovations in infusion pumps and catheter designs have made PN more user-friendly and safer, encouraging broader adoption. The shift towards home care settings, driven by the need to reduce hospital stays and healthcare costs, has expanded the application of PN outside traditional hospital environments. PN`s integration into palliative care enhances the quality of life for patients with severe illnesses who cannot meet their nutritional needs through oral intake alone. Additionally, the aging population, which often faces swallowing difficulties or digestive issues, increases the demand for PN. Increased patient advocacy and awareness, supportive regulatory policies, and expanded insurance and reimbursement coverage also drive the growth and adoption of PN. These factors collectively reflect changes in healthcare systems, technological advancements, and patient preferences, indicating a continued evolution and expansion of PN across various healthcare settings.

Select Competitors (Total 36 Featured) -

• Allergan plc
• Amanta Healthcare Ltd
• B. Braun Melsungen AG
• Baxter International Inc.
• Fresenius KABI AG
• Grifols International S.A.
• ICU Medical Inc.
• Otsuka Pharmaceutical Factory Inc.
• Sichuan Kelun Pharmaceutical Co. Ltd.
• Sino-Swed Pharmaceutical Corp. Ltd.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.